Century Therapeutics (IPSC) Interest Coverage Ratio (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Interest Coverage Ratio of 0.34 for Q1 2026, down 100.18% year-over-year from 186.84 in Q1 2025, and up 99.99% quarter-over-quarter from 3441.83 in Q4 2025.
Century Therapeutics (IPSC) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Interest Coverage Ratio for 7 consecutive years, with 0.34 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 100.18% year-over-year to 0.34; the TTM figure through Mar 2026 stood at 1.66 (up 93.54% YoY), while the FY2025 annual figure was 17.17, down 2288.79% from the prior year.
- Interest Coverage Ratio rose to 0.34 in Q1 2026 per IPSC's latest filing, from 3441.83 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 951.35 in Q4 2023 and bottomed at 3441.83 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 170.96 across 5 years, with a median of 1.68 in 2025.
- On a YoY basis, Interest Coverage Ratio climbed as much as 48954.21% in 2025 and fell as far as 1774441.84% in 2025.
- Century Therapeutics' Interest Coverage Ratio stood at 107.44 in 2022, then surged by 985.48% to 951.35 in 2023, then slumped by 100.02% to 0.19 in 2024, then sank by 1774441.84% to 3441.83 in 2025, then surged by 99.99% to 0.34 in 2026.
- Business Quant data shows IPSC's Interest Coverage Ratio at 0.34 in Q1 2026, 3441.83 in Q4 2025, and 1.68 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | -0.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.65 |
| Mar 31, 2026 | -0.34 |
| Dec 31, 2025 | -3,441.83 |
| Sep 30, 2025 | -1.68 |
| Jun 30, 2025 | -1.44 |
| Mar 31, 2025 | 186.84 |
| Dec 31, 2024 | -0.19 |
| Sep 30, 2024 | -0.40 |
| Jun 30, 2024 | -0.37 |
| Mar 31, 2024 | -0.38 |
| Dec 31, 2023 | 951.35 |
| Sep 30, 2023 | -69.31 |
| Jun 30, 2023 | -4.36 |
| Mar 31, 2023 | -79.41 |
| Dec 31, 2022 | -107.44 |
| Sep 30, 2022 | -85.09 |
| Jun 30, 2022 | -95.00 |
| Mar 31, 2022 | -157.29 |
| Dec 31, 2021 | -114.64 |
| Sep 30, 2021 | -80.21 |